Abstract:Recent evidence indicates that measures from cerebrospinal fluid, MRI scans and cognitive testing obtained from cognitively normal individuals can be used to predict likelihood of progression to mild cognitive impairment several years later, for groups of individuals. However, it remains unclear whether these measures are useful for predicting likelihood of progression for an individual. The increasing focus on early intervention in clinical trials for Alzheimer's disease emphasizes the importance of improving the ability to identify which cognitively normal individuals are more likely to progress over time, thus allowing researchers to efficiently screen participants, as well as determine the efficacy of any treatment intervention. The goal of this study was to determine which measures, obtained when individuals were cognitively normal, predict on an individual basis, the onset of clinical symptoms associated with a diagnosis of mild cognitive impairment due to Alzheimer's disease. Cognitively normal participants (n = 224, mean baseline age = 57 years) were evaluated with a range of measures, including: cerebrospinal fluid amyloid-β and phosphorylated-tau, hippocampal and entorhinal cortex volume, cognitive tests scores and APOE genotype. They were then followed to determine which individuals developed mild cognitive impairment over time (mean follow-up = 11 years). The primary outcome was progression from normal cognition to the onset of clinical symptoms of mild cognitive impairment due to Alzheimer's disease at 5 years post-baseline. Time-dependent receiver operating characteristic analyses examined the sensitivity and specificity of individual measures, and combinations of measures, as predictors of the outcome. Six measures, in combination, were the most parsimonious predictors of transition to mild cognitive impairment 5 years after baseline (area under the curve = 0.85; sensitivity = 0.80, specificity = 0.75). The addition of variables from each domain significantly improved the accuracy of prediction. The incremental accuracy of prediction achieved by adding individual measures or sets of measures successively to one another was also examined, as might be done when enrolling individuals in a clinical trial. The results indicate that biomarkers obtained when individuals are cognitively normal can be used to predict which individuals are likely to develop clinical symptoms at 5 years post-baseline. As a number of the measures included in the study could also be used as subject selection criteria in a clinical trial, the findings also provide information about measures that would be useful for screening in a clinical trial aimed at individuals with preclinical Alzheimer's disease.

Subtle Cognitive Impairment As a Marker of Alzheimer's Pathologies and Clinical Progression in Cognitively Normal Individuals

Altered Functional Connectivity Pattern of Hippocampal Subfields in Individuals with Objectively-Defined Subtle Cognitive Decline and Its Association with Cognition and Cerebrospinal Fluid Biomarkers

Alteration of Functional Connectivity Network in Population of Objectively-Defined Subtle Cognitive Decline.

Prediction of clinical progression of subjective cognitive decline through alterations in morphology and structural covariance networks

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Neurophysiological Signatures of Cognitive Impairment Based on Cortical Plasticity and Cholinergic Modulation

Biomarkers for predicting cognitive decline in those with normal cognition.

Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties.

Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years

Brain structure, amyloid, and behavioral features for predicting clinical progression in subjective cognitive decline

P4‐287: PREDICTION OF 7‐YEAR PROGRESSION FROM SUBJECTIVE COGNITIVE DECLINE TO MCI: EVIDENCE FROM THE CHINA LONGITUDINAL AGEING STUDY (CLAS)

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum

Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study

Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration

Domain-Specific Cognitive Trajectories among Patients with Minor Stroke or Transient Ischemic Attack in a 6-Year Prospective Asian Cohort: Serial Patterns and Indicators.

Prediction of Cognitive Progression Due to Alzheimer's Disease in Normal Subjects Based on Individual Default Mode Network Metabolic Connectivity Strength

New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease.

Prediction of disease progression in individuals with subjective cognitive decline using brain network analysis

STRUCTURAL ABNORMALITIES OF LIMBIC SYSTEM SERVE AS POTENTIAL BIOMARKERS FOR THE ONSET AND PROGRESSION OF MILD COGNITIVE IMPAIRMENT

Cerebral Small Vessel Disease Burden Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer's Disease

Altered cortical and subcortical morphometric features and asymmetries in the subjective cognitive decline and mild cognitive impairment